Analysts Set BeiGene, Ltd. (NASDAQ:BGNE) PT at $251.70

BeiGene, Ltd. (NASDAQ:BGNE) has been given an average recommendation of “Moderate Buy” by the nine ratings firms that are currently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1-year price target among analysts that have covered the stock in the last year is $251.70.

A number of equities analysts recently commented on the stock. Guggenheim reduced their price objective on shares of BeiGene from $350.00 to $345.00 and set a “buy” rating for the company in a research note on Tuesday, February 27th. Bank of America dropped their price objective on BeiGene from $179.30 to $164.30 and set a “neutral” rating on the stock in a research report on Monday, April 8th. Sanford C. Bernstein decreased their price target on shares of BeiGene from $196.00 to $161.00 and set a “market perform” rating for the company in a research report on Wednesday, March 27th. Finally, JPMorgan Chase & Co. raised their price target on shares of BeiGene from $184.00 to $186.00 and gave the company an “overweight” rating in a report on Tuesday, March 19th.

BeiGene Trading Down 1.8 %

Shares of NASDAQ BGNE opened at $129.52 on Friday. BeiGene has a twelve month low of $126.97 and a twelve month high of $266.67. The firm has a market cap of $12.39 billion, a PE ratio of -15.24 and a beta of 0.61. The business has a fifty day simple moving average of $155.08 and a two-hundred day simple moving average of $168.22. The company has a quick ratio of 2.09, a current ratio of 2.32 and a debt-to-equity ratio of 0.06.

BeiGene (NASDAQ:BGNE) last released its quarterly earnings data on Monday, February 26th. The company reported ($3.53) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.61) by $0.08. BeiGene had a negative net margin of 35.86% and a negative return on equity of 23.12%. The company had revenue of $634.40 million during the quarter, compared to analyst estimates of $632.52 million. During the same period in the prior year, the firm earned ($4.29) earnings per share. The firm’s revenue for the quarter was up 66.9% compared to the same quarter last year. Analysts expect that BeiGene will post -8.87 earnings per share for the current fiscal year.

Insider Buying and Selling at BeiGene

In other news, CFO Julia Aijun Wang sold 397 shares of BeiGene stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $167.08, for a total transaction of $66,330.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CFO Julia Aijun Wang sold 397 shares of the firm’s stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $167.08, for a total value of $66,330.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO John Oyler sold 26,716 shares of BeiGene stock in a transaction dated Wednesday, April 10th. The stock was sold at an average price of $148.89, for a total value of $3,977,745.24. Following the sale, the chief executive officer now directly owns 12,084 shares of the company’s stock, valued at approximately $1,799,186.76. The disclosure for this sale can be found here. In the last quarter, insiders have sold 64,781 shares of company stock worth $10,222,381. 7.40% of the stock is owned by corporate insiders.

Institutional Trading of BeiGene

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. PNC Financial Services Group Inc. boosted its holdings in BeiGene by 26.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 244 shares of the company’s stock valued at $54,000 after purchasing an additional 51 shares during the last quarter. Toronto Dominion Bank grew its holdings in BeiGene by 166.4% during the third quarter. Toronto Dominion Bank now owns 333 shares of the company’s stock worth $60,000 after acquiring an additional 208 shares during the period. Knights of Columbus Asset Advisors LLC raised its position in BeiGene by 20.5% during the third quarter. Knights of Columbus Asset Advisors LLC now owns 447 shares of the company’s stock valued at $80,000 after acquiring an additional 76 shares in the last quarter. Benjamin F. Edwards & Company Inc. acquired a new position in BeiGene in the fourth quarter valued at approximately $98,000. Finally, Steward Partners Investment Advisory LLC boosted its position in BeiGene by 73.5% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 694 shares of the company’s stock worth $125,000 after purchasing an additional 294 shares in the last quarter. Institutional investors and hedge funds own 48.55% of the company’s stock.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.